Tag Archives: ML7710

Modulight Spotlights: LASER-SHARP RESEARCH – March 2025

March 19, 2025 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – March 2025 Bladder cancer is the fourth most common cancer in men, and despite good prognosis, recurrences are very common with standard therapies. In a new publication by Jonathan Coleman and the group at the Memorial Sloan Kettering Cancer Center, vascular-targeted therapy was studied for bladder cancer as a minimally invasive treatment option. The therapy involves a photosensitive drug, padeliporfin, which binds to blood albumin and accumulates to tumor vasculature. When the bladder was illuminated with the Modulight’s ML7710 laser, Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – January 2025

January 22, 2025 by Modulight Content
No comments
   Modulight Spotlights: LASER-SHARP RESEARCH – January 2025 We are pleased to highlight this month a new study published in Cancer Immunology, Immunotherapy by Hisataka Kobayashi’s team at National Cancer Institute, NIH. They developed light-activated immunotherapy targeting a specific protein found on the surface of many cancer cells, called tissue factor. This therapy consists of antibody-photoabsorber conjugate that binds to cancer cell surface, and in response to near-infrared light, induces photochemical reaction that results in membrane destruction and immunogenic cell death. When this novel agent was Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – December 2024

December 17, 2024 by Modulight Content
No comments
   Modulight Spotlights: LASER-SHARP RESEARCH – December 2024 This month we are highlighting work by Timothy C. Zhu and the team at University of Pennsylvania, USA. They have investigated the use of photodynamic therapy for mesothelioma, an aggressive cancer that usually occurs in the thin layer of tissue that lines the lungs and is typically caused by asbestos exposure. 24 malignant pleural mesothelioma patients were treated with photodynamic therapy using Photofrin and the ML7710 laser following surgical tumor debulking. The researchers derived oxygenation information inside the Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – August 2024

August 7, 2024 by Modulight Content
No comments
                    Modulight Spotlights: LASER-SHARP RESEARCH – August 2024 This month’s research highlight goes to Hirofumi Hanaoka and the team at Kansai Medical University, Japan. They developed a new laser fiber and method for illumination of narrow cavities, such as esophagus. With typical laser fibers, it is difficult to precisely illuminate target tumor in a narrow space at an oblique angle, since there is not enough space for fiber bending. The new lateral (side) emitting laser fiber was developed and evaluated for near-infrared photoimmunotherapy, which combines light, Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – July 2024

July 26, 2024 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – July 2024 Exciting new findings in prostate cancer research were reported by Xinning Wang and team at Case Western University, Comprehensive Cancer Center. Prostate cancer is the most common cancer among men and despite typically good prognosis, is a leading cause of cancer-related death. In the new study, the team combined chemotherapy with a novel light-activated, theranostic agent to enable targeted imaging and treatment of prostate cancer. Using ML7710 laser at 672 nm for activation of the drug, they were Continue reading →

Comparative study of immune response to local tumor destruction modalities in a murine breast cancer model

June 18, 2024 by Modulight Content
No comments
Published in: Frontiers in Oncology Authors: Sadna Budhu, Kwanghee Kim, Wesley Yip, Stephen La Rosa, Sylvia Jebiwott, Liqun Cai, Aliya Holland, Jasmine Thomas, Dina Preise, Alex Somma, Benjamin Gordon, Avigdor Scherz, Jedd D. Wolchok, Joseph Erinjeri, Taha Merghoub, Jonathan A. Coleman  Published in: Frontiers in Oncology Authors: Sadna Budhu, Kwanghee Kim, Wesley Yip, Stephen La Rosa, Sylvia Jebiwott, Liqun Cai, Aliya Holland, Jasmine Thomas, Dina Preise, Alex Somma, Benjamin Gordon, Avigdor Scherz, Jedd D. Wolchok, Joseph Erinjeri, Taha Merghoub, Jonathan A. Coleman Three forms of localized tumor destruction (radiation therapy, vascular targeted PDT and cryoablation) were compared for their efficacy in evoking local and systemic immune responses. This has potential to improve effectiveness of immunotherapy in non-responding patients (cold tumors) by attracting T cells to the Continue reading →

Near‐infrared photoimmunotherapy targeting PD‐L1: Improved efficacy by preconditioning the tumor microenvironment

April 26, 2024 by Modulight Content
No comments
Published in: Cancer Science Authors: Fuyuki F. Inagaki, Makoto Kano, Aki Furusawa, Takuya Kato, Ryuhei Okada, Hiroshi Fukushima, Seiichiro Takao, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi  Published in: Cancer Science Authors: Fuyuki F. Inagaki, Makoto Kano, Aki Furusawa, Takuya Kato, Ryuhei Okada, Hiroshi Fukushima, Seiichiro Takao, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi In this study, the efficacy of PD-L1-targeted NIR-PIT (photoimmunotherapy) with ML7710 was assessed in immune-competent tumor mouse models. PIT showed a significant therapeutic effect on the tumor models with high PD-L1 expression. Furthermore, it induced an abscopal effect on distant tumors and long-term immunological memory. Combination with interferon-gamma improved the treatment efficacy by increasing PD-L1 expression leading to more Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – April 2024

April 10, 2024 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – April 2024 First-in-human, phase 1 clinical trial results with ML7710 have been published in a renowned journal Radiology by Timothy Baran and team at University of Rochester Medical Center. The trial investigated treatment of deep tissue abscesses using photodynamic therapy with methylene blue and ML7710 laser. Abscesses are painful collection of pus, usually caused by a bacterial infection. Standard treatment is abscess drainage and antibiotics, however treatment responses vary widely and are linked to prolonged hospital stay, costs, and patient discomfort, as well as increasing concerns for antibiotic-resistance. The trial in 18 Continue reading →

Near-infrared photoimmunotherapy targeting Nectin-4 in a preclinical model of bladder cancer

March 31, 2024 by Modulight Content
No comments
Published in: Cancer Letters Authors: Hiroshi Fukushima, Seiichiro Takao, Aki Furusawa, Vladimir Valera Romero, Sandeep Gurram, Takuya Kato, Shuhei Okuyama, Makoto Kano, Peter L. Choyke, Hisataka Kobayashi  Published in: Cancer Letters Authors: Hiroshi Fukushima, Seiichiro Takao, Aki Furusawa, Vladimir Valera Romero, Sandeep Gurram, Takuya Kato, Shuhei Okuyama, Makoto Kano, Peter L. Choyke, Hisataka Kobayashi Enfortumab vedotin (EV), an antibody-drug conjugate (ADC) that targets Nectin-4, has shown promising results in the treatment of bladder cancer. The study investigated use of Nectin-4 targeting photoimmunotherapy in preclinical bladder cancer models. ML7710 was used as light source for activating the therapy in vitro and in vivo.   Read the article here

Phototruncation cell tracking with near-infrared photoimmunotherapy using heptamethine cyanine dye to visualise migratory dynamics of immune cells

March 14, 2024 by Modulight Content
No comments
Published in: eBioMedicine Authors: Hiroshi Fukushima, Aki Furusawa, Seiichiro Takao, Siddharth S. Matikonda, Makoto Kano, Shuhei Okuyama, Hiroshi Yamamoto, Peter L. Choyke, Martin J. Schnermann, Hisataka Kobayashi  Published in: eBioMedicine Authors: Hiroshi Fukushima, Aki Furusawa, Seiichiro Takao, Siddharth S. Matikonda, Makoto Kano, Shuhei Okuyama, Hiroshi Yamamoto, Peter L. Choyke, Martin J. Schnermann, Hisataka Kobayashi A new method called phototruncation-assisted cell tracking (PACT) can be used to noninvasively track migration of immune cells to understand anti-cancer immunity mechanisms. PACT is based on irreversible photo-induced truncation reaction, transforming Cy7 into Cy5 when exposed to NIR light (780 nm). PACT was used in this study to monitor spatiotemporal migration of immune cells between tumor and Continue reading →